Technical Analysis for MYOS - MYOS Corporation

Grade Last Price % Change Price Change
grade D 1.5 2.74% 0.04
MYOS closed up 2.74 percent on Thursday, March 21, 2019, on 19 percent of normal volume.

Earnings due: Mar 25

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Down Up
See historical MYOS trend table...

Date Alert Name Type % Chg
Mar 21 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Mar 21 Crossed Above 20 DMA Bullish 0.00%
Mar 21 Boomer Buy Setup Bullish Swing Setup 0.00%
Mar 21 Calm After Storm Range Contraction 0.00%
Mar 20 Fell Below 20 DMA Bearish 2.74%
Mar 20 Fell Below 50 DMA Bearish 2.74%
Mar 20 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 2.74%
Mar 20 Inside Day Range Contraction 2.74%
Mar 20 Upper Bollinger Band Touch Strength 2.74%
Mar 19 Crossed Above 20 DMA Bullish -11.57%

Older signals for MYOS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

MYOS Corporation, a development-stage biotherapeutics and nutritional products company, focuses on the discovery, development, and commercialization of nutritional supplements, functional foods, therapeutic products, and other technologies for maintaining or improving the health and performance of muscle tissue. It develops MYO-T12, a dietary supplement product for optimizing biological activity. The company was formerly known as Atlas Therapeutics Corporation and changed its name to MYOS Corporation in May 2012. MYOS Corporation was founded in 2007 and is based in Cedar Knolls, New Jersey.
Contents Nutrition Therapeutic Products Dietary Supplement
Is MYOS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Feb 27 MYOS RENS Technology Announces Initiation of a Study at Kansas State University to Evaluate the Impact of Fortetropin® on Quality of Life and Activity in Geriatric Dogs
Feb 21 Should You Be Concerned About MYOS RENS Technology Inc.’s (NASDAQ:MYOS) Historical Volatility?
Feb 19 Report: Exploring Fundamental Drivers Behind Crocs, Portola Pharmaceuticals, ANSYS, Alpha and Omega Semiconductor, PetMed Express, and MYOS RENS Technology — New Horizons, Emerging Trends, and Upcoming Developments
Feb 7 MYOS RENS Technology Announces First Endorsement Deal for Yolked® with NBA Superstar Aaron Gordon
Jan 24 MYOS: Positive Results of Canine Muscle Recovery Study Should Benefit Uptake, Inform Human Development Programs
Jan 23 MYOS CEO Joseph Mannello Issues Letter to Shareholders Following Presentation at North American Veterinary Community (NAVC) Conference/VMX
Jan 15 Myos Rens up 30% on positive data in study evaluating Fortetropin for muscle atrophy in dogs
Jan 15 MYOS RENS Technology Announces Study Results Demonstrating Fortetropin®, the Active Ingredient in Myos Canine Muscle Formula, Prevents Muscle Loss in Canines After Surgery and Enhances Recovery
Jan 8 MYOS RENS Technology Announces Upcoming Presentation of Results from a Kansas State University Study Evaluating the Impact of Fortetropin® on Canine Muscle Loss after Surgery, at a Major Veterinary Conference, January 20, 2019
Jan 3 MYOS RENS Technology receives a new patent from the United States Patent and Trademark Office
See more MYOS news...
Indicator Value
52 Week High 2.5
52 Week Low 1.04
Average Volume 54,018
200-Day Moving Average 1.3948
50-Day Moving Average 1.6109
20-Day Moving Average 1.485
10-Day Moving Average 1.465
Average True Range 0.1345
ADX 32.22
+DI 29.7349
-DI 12.7185
Chandelier Exit (Long, 3 ATRs ) 1.6165
Chandelier Exit (Short, 3 ATRs ) 1.7535
Upper Bollinger Band 1.6316
Lower Bollinger Band 1.3384
Percent B (%b) 0.55
BandWidth 19.744108
MACD Line -0.0273
MACD Signal Line -0.0409
MACD Histogram 0.0136
Fundamentals Value
Market Cap 8.77 Million
Num Shares 5.85 Million
EPS -0.75
Price-to-Earnings (P/E) Ratio -2.00
Price-to-Sales 29.96
Price-to-Book 1.62
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.62
Resistance 3 (R3) 1.62 1.57 1.60
Resistance 2 (R2) 1.57 1.54 1.58 1.59
Resistance 1 (R1) 1.54 1.52 1.56 1.54 1.59
Pivot Point 1.49 1.49 1.50 1.50 1.49
Support 1 (S1) 1.46 1.46 1.48 1.46 1.41
Support 2 (S2) 1.41 1.44 1.42 1.41
Support 3 (S3) 1.38 1.41 1.40
Support 4 (S4) 1.38